| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 64
| Issue : 4 | Page : 687-692 |
|
|
Expression of VEGF-A, HER2/neu, and KRAS in gall bladder carcinoma and their correlation with clinico-pathological parameters
Pomilla Singh1, Shyam Lata Jain2, Puja Sakhuja3, Anil Agarwal4
1 Bharati Vidyapeeth Deemed to be University Medical College, Pune, Maharashtra; Department of Pathology, Maulana Azad Medical College, New Delhi, India
2 Department of Pathology, Maulana Azad Medical College, New Delhi, India
3 Department of Pathology, GB Pant Institute of Post Graduate Medical Education and Research, New Delhi, India
4 Department of GI Surgery, GB Pant Institute of Post Graduate Medical Education and Research, New Delhi, India
Correspondence Address:
Pomilla Singh
5/5 Stavley Road, Near Wanowarie Post Office, Pune - 411 040, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/IJPM.IJPM_248_20
|
|
|
Background: Gall bladder carcinoma (GBC) is a multi-factorial disease, involving multiple genetic alterations. The present pilot study aims to explore some of the molecular pathways, by studying immunohistochemical (IHC) expression of biomarkers (HER2/neu, KRAS, and VEGF) in GBC with their correlation with various clinicopathological parameters. Aim of the Study: To study the expression of prognostic biomarkers (HER2/neu, KRAS and VEGF-A) in GBC and their correlation with clinico-morphological parameters. Materials and Methods: This prospective study was conducted over a period of 2 years. The study group included tissue of GBC (29) reported as malignant on histopathology and cholecystitis as a control group (29) for histopathological evaluation and IHC expression of above markers. Results: HER2/neu was expressed in 27.5% cases, and KRAS in 51.6%; however, both showed no association with tumor type, stage and grade. No association was found in KRAS expression and dysplasia. Vascular Endothelial Growth Factor - A (VEGF-A) was expressed in 86.1% cases, of which strong positivity was seen in 48.27%; it showed significant association with tumor stage (P value-0.027, Fishers' exact test), hence possibly suggesting its role in tumor progression; though no association was found in VEGF expression with tumor type and grade. No significant association was seen with vascular and tumor invasion also. Conclusion: The results suggest that the VEGF-A expression may be used as a potential prognostic biomarker in GBC.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
